Mental health disorders Flashcards

1
Q

Anxiety treatment

A
  • Benzodiazepines are indicated for short-term relief of anxiety that is causing unacceptable distress (for 2-4 weeks only). An example is Diazepam
  • They can slow down the grieving process and are used in children only for acute anxiety in situations involving fear (e.g. fear of surgery).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Symptoms of diazepam overdose

A

drowsiness, ataxia, dysarthria, nystagmus + coma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

For chronic anxiety

A

Chronic - (longer than 4 weeks) it may be appropriate to use an antidepressant.

  • Patients with generalised anxiety disorder (a form of chronic anxiety), should be offered psychological treatment followed by an SSRI (sertraline).
  • Duloxetine and Venlafaxine (serotonin and noradrenaline re-uptake inhibitors) can also be used.
  • If a patient cannot tolerate the above/treatment is ineffective, then pregabalin can be considered
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Attention deficit hyperactivity disorder (ADHD)

A

If a child has severe and persistent symptoms of ADHD, then CNS stimulants including Atomoxetine + Methylphenidate can be prescribed

  • If a child has moderate symptoms of ADHD they can be treated with CNS stimulants when psychological interventions have been unsuccessful or are unavailable.
  • Treatment for ADHD often needs to continue into adolescence and may need to be continued into adulthood.
  • If the patient does not respond to Atomoxetine and Methylphenidate, then Dexamfetamine and Lisdexamfetamine are an alternative for children.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

ADHD - what can be used in children for whom stimulants are not suitable, not tolerated or ineffective

A

Guanfacine, a non-stimulant alpha2-adrenoceptor agonist

  • Therapeutic response to guanfacine should be evaluated every 3 months for the first year, and then atleast yearly, when prescribed for extended periods.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Atomoxetine - monitoring requirements

A

Monitor for appearance or worsening of anxiety, depression or tics. Pulse, BP, psychiatric symptoms, appetite, weight and height should be recorded at initiation of therapy, following each dose adjustment and 6 months thereafter.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Atomoxetine - patient/carer advice

A

Suicidal ideation: following reports of suicidal thoughts and behaviour, patients and their carers should be informed about the risk and told to report worsening suicidal thoughts/behaviour, irritability, agitation or depression.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Atomoxetine - hepatic impairment

A

Recognise and report symptoms such as abdominal pain, unexplained nausea, malaise, darkening of urine or jaundice

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Dexamfetamine + Lisdexamfetamine

Cautions:

A
  1. Tics and Tourette syndrome: discontinue use if tics occurs.
  2. Growth restriction in children may occur during prolonged therapy, monitor height and weight (drug-free periods may allow catch-up in growth.. withdraw slowly to avoid inducing depression,renewed hyperactivity)
  • Overdose: wakefulness, excessive activity, paranoia, hallucinations, HTN, exhaustion, convulsions, coma and hyperthermia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Bipolar disorder and Mania

A

Bipolar disorder is a condition that affects moods, which can swing from one extreme to another. People with bipolar disorder often have periods or episodes of:

  • Depression – feeling very low and lethargic
  • Mania – feeling very high and overactive
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

used to treat mania or hypomania.

A

Antimanic drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Antidepressant drugs are used to treat co-existing depression but should be avoided in patients with

A

rapid-cycling bipolar disorder, a recent history of hypomania or with rapid mood fluctuations.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q
  • Long term treatment of bipolar disorder
A

should continue for atleast 2 years from the last manic episode and up to 5 years if the patient has risk factors for relapse.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Benzodiazepines may be helpful in

A

• Benzodiazepines (e.g. Lorazepam) may be helpful in initial stages of treatment for behavioural disturbance or agitation. But they should not be used for long-periods due to the risk of dependence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Antipsychotic drugs

A
  • Antipsychotic drugs (normally olanzapine, quetiapine or risperidone) are useful to treat acute episodes of mania or hypomania. If they are effective in controlling manic episodes, they can be used for the long-term management of BIPOLAR DISORDER.
  • Antipsychotic drugs can be given as monotherapy or in combination with lithium or valproate, if patient has frequent relapses or continuing functional impairment.
  • For severe acute mania, an antipsychotic drug may be used concomitantly with lithium or valproate.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Carbamazepine

A

• If patients are unresponsive to a combination of prophylactic drugs, Carbamazepine may be used under specialist supervision for the prophylaxis of bipolar disorder (manic-depressive disorder).
• It is used in patients with rapid-cycling manic-depressive illness (4 or more episodes per year)
- The dose of this drug should not normally be increased if an acute episode of mania occurs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Valproate

A
  • Valproate includes Sodium Valproate and Valproic acid (semi-sodium salt). Valproic acid is available as Depakote and Convulex which are licensed for manic episodes associated with bipolar disorder.
  • Sodium Valproate is available as Epilim and Epilim Chrono which are licensed for epilepsy + mania
  • If the patient has frequent relapses or continuing functional impairment, consider switching therapy to lithium or olanzapine or adding lithium or olanzapine to valproate.
  • If a patient taking valproate experiences an acute episode of mania that is not improved by increasing the valproate dose, consider adding olanzapine, quetiapine or risperidone.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Lithium

A

 Lithium salts are used as a mood-stabiliser in bipolar disorder, but it can take 6-12 months for the effect to be seen.
 Cautions: Long-term use of lithium has been associated with thyroid disorders and mild cognitive and memory impairment… hence long-term treatment should be undertaken with careful assessment of risk and benefit and thyroid function should be monitored every 6 months.
 Driving and skilled tasks: this drug may impair performance of skilled tasks (e.g. driving).
 Renal function should also be monitored every 6 months.
 The bioavailability of preparations vary, therefore lithium should ALWAYS BE PRESCRIBED BY BRAND (e.g. Priadel or Camcolit).
 Dose equivalence and conversion: for Priadel liquid: 520mg of Lithium Citrate Tetrahydrate is equivalent to 204mg of Lithium Carbonate.

 Patients should be issued with a lithium treatment pack and advised to maintain adequate fluid intake and avoid changing the amount of salt in their diet.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Depression

A

• Antidepressants should only be used for moderate to severe illness. However, if psychological therapy is ineffective in patients with mild depression, drug treatment may be considered.

  • Alternatively, drug treatment for mild depression may be considered if the patient has a history of moderate-severe depression or if they have social/medical problems.
  • Most antidepressant drugs are equally effective, so the choice of antidepressant depends on the patient’s needs, co-morbidities, risk of suicide and previous response to antidepressant therapy.

 Antidepressants take 2 weeks for the full effect to be seen, and during this time there may be an increase in agitation, anxiety and suicidal ideation. When initiating treatment, patients should be assessed every 1-2 weeks.
 Treatment should be continued for atleast 4 weeks (6 weeks in elderly) before considering a change in treatment.
 Following remission, antidepressant treatment should be continued at the same dose for atleast 6 months (12 months in elderly). Therapy should continue for atleast 2 years in patients with a history of recurrent depression.
 SSRIs (e.g. Sertraline) are the first-line treatment option since they are safer in overdose than other antidepressants.
 TCA’s have a similar efficacy to SSRIs but are more likely to be discontinued due to side effects. Furthermore, they are more toxic (harmful to the body) in overdose.
 MAOIs have dangerous interactions with certain foods + drugs and are reserved for specialist use.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What drugs should be used in caution in depression

A

Although anxiety is often present in depressive illness (and may be the presenting symptom), the use of an antipsychotic/anxiolytic may mask the true diagnosis. Hence, these drugs should be used in caution but are sometimes added to manage agitation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

St John’s wort

A

 St John’s wort is a popular herbal remedy available OTC for treating mild depression. It SHOULD NOT be prescribed or recommended for depression because it can induce drug metabolising enzymes and has many interactions with conventional (common) drugs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Side effect of all antidepressants

A

HYPONATRAEMIA (low sodium levels in the blood) is a side effect of ALL antidepressants, and it has been reported more frequently in SSRIs. Patients should be advised to look out for symptoms: drowsiness, confusion and convulsions.

  • Antidepressants are linked with SUICIDAL thoughts and behaviour –> children, young adults and patients with a history of suicidal behaviour are particularly at risk. Thus, patients should be monitored for suicidal behaviour, self-harm or hostility.
23
Q

Failure to respond to antidepressants: Depression

A
  • If a patient fails to respond to initial treatment with an SSRI, consider increasing the dose or switching to a different SSRI or Mirtazapine
  • Other Second-line choices include Lofepramine, Moclobemide and Reboxetine. Other TCAs and Venlafaxine should be considered for more severe forms of depression.
  • Failure to respond to a second antidepressant may require addition of an augmenting agent (top-up drug) such as Lithium, Olanzapine, Quetiapine or Risperidone or Aripiprazole.
  • ECT (electroconvulsive therapy) may be initiated in severe refractory depression.
24
Q

TCAs

A

• TCAs BLOCK the re-uptake of both serotonin and noradrenaline.
• Examples include Amitriptyline and Nortriptyline. Amitriptyline is more sedative than Nortriptyline.
- Agitated and anxious patients tend to respond best to sedative compounds, whilst withdrawn and apathetic patients tend to respond better to less sedative compounds.
• Amitriptyline can cause antimuscarinic side effects including dry mouth, blurred vision, urinary retention and constipation.
• Furthermore, it may interact with Warfarin, either increasing or decreasing INR level. It may also interact with epileptics.
• Low doses should be used for initial treatment in the elderly. In most patients, the long half-life of TCAs allows ONCE daily dosing usually at night, hence MR preparations are not needed

25
Q

SSRIs

A
  • SSRIs include Citalopram, Escitalopram, Fluoxetine, Paroxetine and Sertraline. Only Fluoxetine has been proven to be effective in children and adolescents.
  • Serotonin syndrome (or serotonin toxicity) is an uncommon side effect of SSRIs, caused by high levels of serotonin. Symptoms include neuromuscular hyperactivity (tremor, muscle spasm, rigidity, etc.), autonomic dysfunction (tachycardia, hyper/hypotension, hyperthermia, shivering, diarrhoea etc.) and altered mental state (agitation, confusion and mania).
  • Onset of symptoms can occur within hours or days following the initiation, dose escalation, overdose, the addition of a new serotonergic drug or the replacement of one serotonergic drug by another.
  • Treatment involves withdrawing the serotonergic medication
  • SSRIs may interact with drugs which increase the risk of bleeding including Warfarin, Antiepileptics and other antidepressants/antipsychotics.
  • Overdose: symptoms of poisoning by SSRIs include nausea, vomiting, agitation, tremor, nystagmus, sinus tachycardia and drowsiness; convulsions may occur.
  • Treatment cessation: GI disturbances, headache, anxiety, dizziness, paraesthesia, electric shock sensation in head/neck/spine, tinnitus, sleep disturbances, fatigue, influenza like symptoms and sweating are the most common features of abrupt withdrawal of an SSRI or marked reduction of dose.
  • The risk of withdrawal reactions is higher for Paroxetine and Venlafaxine
  • The dose should be tapered over a few weeks to avoid these effects.
26
Q

Monoamine Oxidase Inhibitors (MAOIs)

A
  • Used much less frequently than TCAs and SSRIs due to the dangers of dietary and drug interactions.
  • Examples include: Isocarboxazid, Phenelzine, Tranylcypromine, Moclobemide
  • Phobic and depressed patients are said to respond best to MAOIs. However, they should be tried in patients who are refractory to other antidepressant treatment as there is occasionally a dramatic response.
  • Response to treatment may take >3 weeks, and the full effect may not be seen for an additional 1-2 weeks.
  • Risk of postural hypotension and hypertensive responses. If palpitations or frequent headaches occur
  • Treatment cessation: if possible, avoid abrupt withdrawal. Withdrawal symptoms on cessation of therapy include agitation, irritability, insomnia, drowsiness, etc. Hence, they should be withdrawn slowly (over about 4 weeks) or longer if withdrawal symptoms emerge.
  • Eat only fresh foods and avoid food that is suspected to be stale or going off. Avoid alcohol
27
Q

MAOIs interactions

A

• Interactions:
 Other antidepressants should not be started for 2 weeks after treatment with an MAOI has stopped (3 weeks if staring clomipramine or imipramine)
 In contrast an MAOI should not be started until:
o Atleast 2 weeks after a previous MAOI has stopped (then started at a reduced dose)
o Atleast 7-14 days after a TCA has been stopped (3 weeks in the case of clomipramine or imipramine)
o Atleast a week after an SSRI has been stopped (atleast 5 weeks in the case of fluoxetine).

28
Q

Agomelatine (melatonin receptor agonist + SSRI, doesn’t affect uptake of serotonin, noradrenaline or dopamine)

A
  • Side effects: suicidal behaviour  Monitor patients
  • Hepatoxicity: advise patients how to recognise signs of liver disorder and seek immediate attention if symptoms: dark urine, light coloured stools, jaundice, bruising, fatigue, abdominal pain or Pruritis develop.
29
Q

All antipsychotic drugs can precipitate…. in patients with hepatic impairment

A

coma

30
Q

Psychoses and related disorders: 1st gen antipsychotic drugs:

A

First-generation Antipsychotic drugs act mostly by blocking Dopamine D2 receptors in the brain. They are not selective for any of the 4 dopamine pathways in the brain so can cause a range of side effects including Extrapyramidal side effects and raised prolactin (see later).
- Examples include Chlorpromazine, Haloperidol and Flupentixol

31
Q
  1. Second-generation
A

Second-generation Antipsychotics act on a range of receptors in the brain and are more distinct than first-generation antipsychotics, particularly with regard to side effects.
- Examples include Aripiprazole, Clozapine, Olanzapine and Risperidone
Patients should have just 1 Antipsychotic at a time, and treatment should be reviewed after 4-6 weeks

32
Q

Advice of Royal College of Psychiatrists on doses of Antipsychotic drugs above BNF upper limit

A

Unless otherwise stated, doses in the BNF are licensed doses – any higher dose is therefore unlicensed.

  • Consider adjuvant therapy and newer or second-generation antipsychotic drugs such as Clozapine.
  • Bear in mind risk factors (e.g. obesity as antipsychotic drugs cause weight gain), particular caution is indicated in older patients – especially those >70
  • Consider potential for drug interactions
  • Carry out an ECG to exclude abnormalities such as prolonged QT interval. Repeat the ECG periodically and reduce dose if prolonged QT interval or other adverse cardiac abnormality develops
  • Increase the dose slowly… and not more often than once weekly
  • Carry out regular pulse, BP and temperature checks, ensure that patient maintains adequate fluid intake
  • Consider high-dose therapy to be for limited period and review regularly. Abandon if no improvement after 3 months (return to standard dosage).
33
Q

Prescribing for the elderly: antipsychotic drugs

A
  • In elderly patients with dementia, antipsychotic drugs are associated with a small increased risk of mortality + an increased risk of stroke or transient ischaemic attack
  • Furthermore, elderly patients are susceptible to postural hypotension and to hyper- and hypothermia in hot or cold weather.

It is recommended that:
• Antipsychotic drugs should not be used in the elderly to treat mild or moderate psychotic symptoms
• Initial doses of antipsychotic drugs in elderly patients should be REDUCED (to HALF the adult dose or LESS).
• Treatment should be reviewed regularly.

34
Q

Side effects of antipsychotic drugs

A

Extrapyramidal symptoms (most likely with piperazine phenothiazines, butyrophenones + 1st gen. depot preparations)

  1. Parkinsonian symptoms: (including tremor) appear gradually + commonly in adults & elderly. Parkinsonian symptoms disappear upon withdrawal of drug and may be supressed by antimuscarinic drugs. However routine administration of antimuscarinics is not advised because they may unmask/worsen tardive dyskinesia.
  2. Dystonia: (abnormal face + body movements) and dyskinesia (impaired voluntary movements) which occur more commonly in children + young adults & appear after only a few doses
  3. Akathisia: (restlessness) which occurs after large initial doses and may resemble an exacerbation of the condition being treated.
  4. Tardive dyskinesia: (rhythmic, involuntary movements of the tongue, face and jaw), which usually develops on long-term therapy or with high dosage. But it may develop on short-term treatment with low doses –> short-lived tardive dyskinesia may occur after withdrawal of drug. This side effect may be irreversible upon withdrawal of therapy and treatment is usually ineffective.
35
Q

piperazine phenothiazines examples

A

Fluphenazine, Perphenazine, Prochlorperazine, Trifluoperazine

36
Q

butyrophenones examples

A

Benperidol, Haloperidol

37
Q

Hypotension and interference with temperature regulation: antipsychotics

A

 Hypotension and interference with temperature regulation are dose related side effects that are liable to cause dangerous falls and either hypo or hyperthermia in the elderly.
 Clozapine and Quetiapine can cause postural hypotension (especially during dose initiation) which may be associated with syncope (temporary loss of consciousness) or reflex tachycardia.

38
Q

Other side effects of antipsychotics.

A
  1. Hyperprolactinaemia: is a side effect of most antipsychotics (most likely risperidone, amisulpride + 1st gen.) which can lead to sexual dysfunction, reduced bone mineral density, menstrual disturbances in women, breast enlargement in men and galactorrhoea (except aripiprazole which reduces prolactin levels)
  2. Weight gain: all antipsychotics cause weight gain (commonly clozapine & olanzapine) and some may cause hyperglycaemia leading to diabetes  particularly clozapine, olanzapine, quetiapine and risperidone)
  3. Neuroleptic malignant syndrome: is a rare but serious side effect of antipsychotics. It presents as hyperthermia, fluctuating levels of consciousness, muscle rigidity, & autonomic dysfunction with pallor, tachycardia, labile BP, sweating and urinary incontinence
39
Q

Important safety information for drugs: antipsychotics.

A
  • Oral preparations are used in hospital for rapid control of an acute episode
  • Depot injections are used for maintenance treatment
40
Q

Clozapine, chlorpromazine lurasidone & quetiapine can cause

A

postural hypotenstion

41
Q

Haloperidol & pimozide can cause

A

QT-interval prolongation

42
Q

Monitoring: antipsychotics.

A
  • FBC, urea and electrolytes and Liver function tests should be tested at the start of treatment and annually thereafter.
  • Lipids, weight, prolactin, blood pressure and blood glucose should be monitored yearly.
43
Q

Chlorpromazine (1st gen.)

A
  • Side effects: this drug can induce acute dystonic reactions such as facial and skeletal muscle spasms and oculogyric crisis. Children (especially girls, young women) are particularly susceptible. Protect skin from
  • Handling and storage: due to the risk of contact sensitisation, HCPs should avoid direct contact with this drug, tablets should not be crushed, and solutions should be handled with care.
44
Q

Pimozide (1st gen.)

A

• Monitoring requirements: following reports of sudden, unexplained death, an ECG is recommended before treatment. Patients should also have an annual ECG and Pimozide should not be given with other antipsychotics, TCAs or other drugs which prolong QT interval (such as certain antimalarials, antihistamines + antiarrhythmics) and should not be given with drugs that cause electrolyte disturbances (esp. diuretics)

45
Q

Clozapine (2nd gen.)

A
  • Cautions: Agranulocytosis: neutropenia and potentially fatal agranulocytosis reported. Leucocyte and differential blood counts must be normal before starting. Monitor counts every week for 18 weeks then atleast every 2 weeks. If clozapine continued and if blood count stable after 1 year, monitor atleast every 4 weeks (and 4 weeks after discontinuation). If leucocyte count or absolute neutrophil count too low, then discontinue permanently. Avoid drugs which depress leucopoiesis. Patients should report immediately symptoms of infection  especially influenza like illness.
  • Cautions: Fatal Myocarditis (most commonly in first 2 months) and cardiomyopathy reported.
  • Cautions: Intestinal obstruction: caution in patients on drugs that may cause constipation
  • Side effects: Hypersalivation associated with this drug can be treated with hyoscine hydrobromide (unlicensed), provided the patient is not at particular risk from the additive antimuscarinic side effects of hyoscine and clozapine.
  • Monitoring requirements: monitor leucocyte and differential blood counts. Patient must be closely supervised during initiation due to risk of collapse because of hypotension and convulsions. Blood lipids and weight should be measured at baseline, every 3 months for the first year, and then yearly. Fasting blood glucose should be measured at baseline, after 1 month, then every 4-6 months
46
Q

Olanzapine (2nd gen.)

A
  • Cautions: CNS and respiratory depression
  • With IM: Monitor BP, pulse and respiratory rate for at least 4h after IM injection (leave at least 1h between administering olanzapine IM and parenteral benzodiazepines)
47
Q

Benzodiazepines in pregnancy

A

• There is a risk of neonatal withdrawal symptoms when used during pregnancy. Hence regular use must be avoided unless there is a clear indication e.g. seizure control. High doses administered during late pregnancy or labour may cause neonatal hypothermia, hypotonia and respiratory depression.

48
Q

The effects of taking Benzodiazepines range from

A
  • talkativeness and excitement to aggressive and anti-social acts. Adjustment of the dose (up or down) sometimes attenuates the impulses.
  • Drowsiness may persist the next day, and affect performance of skilled tasks such as driving
49
Q

Asenapine

A

• (2nd gen) is licensed for moderate to severe manic episodes associated with bipolar disorder

50
Q

When discontinuing Antipsychotics

A

• the dose should be reduced gradually over atleast 4 weeks if the patient is continuing with other antimanic drugs. If the patient is not continuing with other antimanic drugs or if there is a history of manic relapse, the drug can be withdrawn over a period of up to 3 months.

51
Q

Symptoms of lithium toxicity

A
  • GI disturbances (vomiting, diarrhoea), visual disturbances, polyuria, muscle weakness, fine tremor increasing to coarse tremor, CNS disturbances (confusion and drowsiness), abnormal reflexes, myoclonus, incontinence, hypernatremia.
  • With severe overdosage: seizures, cardia arrythmias, BP changes, circulatory failure, renal failure, coma and sudden death
52
Q

Lithium has a NARROW THERAPEUTIC INDEX, so blood samples should be taken (+ target)

A

 12 hours after a dose (target 0.4-1mmol/L in maintenance therapy, 0.8-1mmol/L in acute episodes). Toxic effects occur above 1.5mmol/l.

53
Q

Lithium toxicity is worsened by

A

 sodium depletion, so concurrent use with diuretics (especially thiazides) should be avoided.